HC Wainwright Reaffirms Buy Rating for TG Therapeutics (NASDAQ:TGTX)

HC Wainwright restated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a $49.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2024 earnings at $0.11 EPS.

TGTX has been the topic of a number of other research reports. LADENBURG THALM/SH SH upped their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a buy rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. reaffirmed an overweight rating and set a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, TG Therapeutics has an average rating of Moderate Buy and a consensus price target of $31.83.

TG Therapeutics Stock Up 0.3 %

Shares of NASDAQ:TGTX opened at $20.04 on Tuesday. The firm has a market capitalization of $3.10 billion, a P/E ratio of 87.13 and a beta of 2.23. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.84 and a current ratio of 3.62. The stock has a 50 day moving average price of $18.67 and a 200-day moving average price of $16.62. TG Therapeutics has a 52-week low of $6.46 and a 52-week high of $23.12.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The business had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same quarter in the prior year, the company earned ($0.34) earnings per share. The firm’s quarterly revenue was up 357.0% compared to the same quarter last year. As a group, equities research analysts anticipate that TG Therapeutics will post -0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TGTX. Eventide Asset Management LLC purchased a new position in shares of TG Therapeutics in the fourth quarter worth $7,506,000. Wellington Management Group LLP raised its position in TG Therapeutics by 1.4% in the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock worth $53,627,000 after buying an additional 43,290 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in TG Therapeutics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,896 shares of the biopharmaceutical company’s stock valued at $19,333,000 after acquiring an additional 19,214 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of TG Therapeutics by 133.5% during the 1st quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock valued at $796,000 after acquiring an additional 29,923 shares during the last quarter. Finally, Corient Private Wealth LLC grew its stake in shares of TG Therapeutics by 231.6% in the fourth quarter. Corient Private Wealth LLC now owns 93,381 shares of the biopharmaceutical company’s stock worth $1,595,000 after acquiring an additional 65,220 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.